Livzon Group Fuzhou Fuxing Pharmaceutical

Executive Summary

Livzon Group Fuzhou Fuxing Pharmaceutical (Fuxing Pharma) is a subsidiary of Livzon Pharmaceutical Group, one of China's leading pharmaceutical companies. Established in 1994, Fuxing Pharma focuses on the research, development, and commercialization of small molecule drugs and biologics, with a particular emphasis on infectious diseases and oncology. Leveraging the extensive resources and distribution network of its parent company, Fuxing Pharma has built a diverse product portfolio that includes both generic and innovative drugs. The company's integrated R&D capabilities and manufacturing infrastructure position it well in China's rapidly evolving pharmaceutical landscape. As a commercial-stage entity, Fuxing Pharma generates steady revenue from existing products while investing in pipeline development. The company benefits from Livzon Group's strong market presence and regulatory expertise, which facilitate faster market access and commercialization. However, Fuxing Pharma faces intense competition in the generic drug segment and evolving regulatory requirements in China. The company's future growth hinges on advancing its pipeline of novel therapeutics and expanding its presence in oncology and infectious disease areas. With China's increasing healthcare spending and aging population, Fuxing Pharma is well-positioned to capture value over the long term.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Trial Result for Oncology Drug60% success
• Q2 2026NDA Submission for Infectious Disease Treatment70% success
• Q3 2026Regulatory Approval for Biosimilar65% success